Group 1 - Company shares of 基石药业-B (02616) increased by over 5%, reaching a price of 6.07 HKD with a trading volume of 22.7042 million HKD [1] - The company announced that its RET inhibitor, 普吉华 (普拉替尼胶囊, 100mg), has been successfully included in the latest National Medical Insurance Catalog, effective from January 1, 2026 [1] - To date, 基石药业 has successfully advanced four innovative drugs to market approval, with three of them having completed clinical trials and registration in China, now included in the national insurance catalog [1] Group 2 - Tianfeng Securities published a report in August, predicting that the inclusion of 普拉替尼 in the insurance catalog is expected to accelerate its market penetration [1] - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] - The innovative internal ADC technology platform of the company features optimized proprietary linkers to improve the selective release of effective payloads in tumors, supporting multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for future development [1]

Group 1 - 基石药业-B (02616) shares rose nearly 4% after the company announced that its drug, Pujihua (Pralsetinib capsules, 100 mg), has been included in the latest National Medical Insurance Drug List, effective January 1, 2026 [1] - Gold stocks generally increased, with Lingbao Gold (03330) up 9.54%, China Silver International (00815) up 4.48%, and Zijin Mining International (02259) up 4.31%. This surge is attributed to the rise in precious metals ahead of the Federal Reserve's decision, with spot silver surpassing $61 per ounce and spot gold exceeding $4,210 per ounce [1] - Oil stocks continued to decline, with PetroChina (00857) down 2.26% and Sinopec (00386) down 1.14%. A warning from commodity trading giant Trafigura indicated a potential "super supply glut" in the oil market due to increased supply coinciding with an economic slowdown [1] Group 2 - Pacific Basin Shipping (02343) fell nearly 9% as the Baltic Dry Index (BDI) dropped to 2,557 points, marking a 5.09% decrease and the largest drop since October 14, 2025 [2] - Xianjian Technology (01302) saw an intraday drop of 8% following an announcement regarding a share reward plan involving the purchase of 230 million shares [2] - China Jinmao (00817) shares rose nearly 6% after reporting a signed sales amount of RMB 7.997 billion in November 2025, with a year-on-year increase of 21.3% in cumulative signed sales [2] Group 3 - Zai Lab (02509) shares increased over 3% after receiving a $5 million milestone payment from Caldera Therapeutics, triggered by the approval of a Phase I clinical trial [3] - Dekang Agriculture (02419) shares rose nearly 4% after reporting sales of approximately 1.0658 million pigs and revenue of about RMB 1.592 billion in November [3] - Yino Pharma (02591) surged over 17.9% after being included in the Stock Connect program, effective December 8, 2025 [3] Group 4 - China Metallurgical Group (01618) shares fell nearly 4% after announcing plans to sell its 100% stake in China Metallurgical Real Estate to China Minmetals [4] Group 5 - The robotics sector in the US stock market remained active, with Nauticus Robotics (KITT.US) up 21.42% and iRobot (IRBT.US) up 11.36%, driven by a shift in policy focus towards robotics [5] - Precious metal stocks showed strong performance, with Pan American Silver (PAAS.US) up 11.16% as spot silver prices reached a new historical high [5] - The storage sector in the US stock market declined, with SanDisk Corp (SNDK.US) down 2.67% following a neutral rating from Morgan Stanley [5] Group 6 - Senti Biosciences (SNTI.US) plummeted 35.56% after reporting updated Phase I data showing a 50% overall response rate in a clinical trial [6] - STAAR Surgical (STAA.US) shares rose over 7.84% after Alcon increased its acquisition offer to approximately $1.6 billion [6] - Ares Management (ARES.US) increased by 7.27% as it is set to join the S&P 500 index, attracting passive investment inflows [6] Group 7 - Wave Life Sciences (WVE.US) continued to rise by 15.06% after announcing positive mid-stage data for its obesity candidate drug WVE-007 [7]

Group 1 - Core viewpoint: 基石药业-B (02616) shares rose over 4%, currently trading at 5.82 HKD with a transaction volume of 24.98 million HKD, following the announcement of its drug being included in the national medical insurance list [1] - The drug, 普吉华 (普拉替尼胶囊, 100 mg), will be officially included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by the National Healthcare Security Administration of China, effective from January 1, 2026 [1] - On December 4, non-executive director 胡正国 increased his stake in 基石药业 by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, raising his total holdings to 3.471 million shares, which represents 0.24% of the company [1]

Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has seen an increase of over 4%, currently trading at 5.82 HKD, with a transaction volume of 24.98 million HKD, following the announcement of its drug being included in the national medical insurance list in China [1] Group 1 - Basestone Pharmaceuticals announced that its drug, Pulatinib (100 mg capsules), has been included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List published by the National Healthcare Security Administration of China, which will take effect on January 1, 2026 [1] - Following this announcement, the stock price of Basestone Pharmaceuticals rose by 3.93% [1] Group 2 - On December 4, the non-executive director Hu Zhengguo increased his holdings in Basestone Pharmaceuticals by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD [1] - After this purchase, Hu Zhengguo's total shareholding in the company increased to 3.471 million shares, representing a holding percentage of 0.24% [1]

Group 1 - The core viewpoint of the article is that 基石药业-B (02616) has seen a stock price increase of over 4%, currently trading at 5.82 HKD, with a transaction volume of 24.98 million HKD [1] - 基石药业's drug, 普吉华 (普拉替尼胶囊, 100 mg), has been included in the latest National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by China's National Healthcare Security Administration, which will take effect on January 1, 2026 [1] - On December 4, the non-executive director 胡正国 increased his holdings in 基石药业 by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, bringing his total holdings to 3.471 million shares, representing 0.24% of the company [1]

Core Viewpoint - The announcement of the inclusion of the drug Pujihua (Pralsetinib capsules, 100mg) in China's National Medical Insurance Catalog has positively impacted the stock price of the company, leading to an increase of over 3% in early trading [1] Group 1: Stock Performance - The stock of the company, 基石药业-B, rose by over 3% in early trading and is currently up by 2.51%, priced at 5.71 HKD with a trading volume of 7.29 million HKD [1] Group 2: Drug Development and Commercialization - Pujihua has been developed by Blueprint Medicines, which was acquired by Sanofi in July 2025 [1] - The company holds exclusive development and commercialization rights for Pujihua in Greater China, including mainland China, Hong Kong, Macau, and Taiwan [1] - In November 2023, the company granted exclusive commercialization rights for Pujihua in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [1] Group 3: Regulatory Approval - The National Medical Insurance Catalog, which includes Pujihua, will officially take effect on January 1, 2026 [1]

Group 1 - The core point of the article is that Basestone Pharmaceuticals' drug, Pujihua (Pralsetinib), has been included in the latest National Medical Insurance Drug List in China, effective from January 1, 2026 [1] - Pujihua is an oral targeted therapy approved for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive, as well as for certain thyroid cancer patients [1] - The drug has already been approved in Hong Kong and Taiwan for similar indications, demonstrating its regional market presence [1] Group 2 - The FDA has approved Pujihua under the brand name GAVRETO for specific indications related to metastatic RET fusion-positive NSCLC and thyroid cancer in adults and children aged 12 and above [2] - Pujihua was developed by Blueprint Medicines, which was acquired by Sanofi in July 2025, while Basestone Pharmaceuticals holds exclusive rights for its development and commercialization in Greater China [2] - In November 2023, Basestone Pharmaceuticals granted exclusive commercialization rights for Pujihua in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [2]

Group 1 - The core announcement is that Basilea Pharmaceutica's drug, Pralsetinib (brand name GAVRETO), has been included in China's National Medical Insurance catalog, effective January 1, 2026 [1] - Pralsetinib is an oral targeted therapy approved for treating adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and other specific thyroid cancers [1][2] - The drug has already received approval in Hong Kong and Taiwan for similar indications, expanding its market presence in Greater China [1] Group 2 - The FDA has approved GAVRETO for the treatment of adult patients with metastatic RET fusion-positive NSCLC and certain thyroid cancers, indicating its acceptance in the U.S. market [2] - Basilea Pharmaceutica holds exclusive development and commercialization rights for Pralsetinib in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [2] - In November 2023, Basilea Pharmaceutica granted exclusive commercialization rights for Pralsetinib in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [2]

Core Viewpoint - The inclusion of the drug Praluent® (Pralsetinib capsules, 100 mg) in China's National Medical Insurance Catalog is a significant development for the company, as it will officially take effect on January 1, 2026, enhancing the drug's market access and potential sales in the region [1]. Group 1: Drug Approval and Indications - Praluent® is an oral targeted therapy approved by the National Medical Products Administration (NMPA) for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive, as well as for adult and pediatric patients aged 12 and above with advanced or metastatic RET mutation medullary thyroid carcinoma (MTC) requiring systemic treatment [1][2]. - The drug has also been approved in Hong Kong for treating adult patients with metastatic RET fusion-positive NSCLC and in Taiwan for similar indications, including advanced or metastatic RET fusion-positive thyroid cancer [1]. Group 2: Commercialization and Partnerships - The drug Praluent® was developed by Blueprint Medicines, which was acquired by Sanofi in July 2025, indicating a strategic partnership that may enhance the drug's development and commercialization efforts [2]. - The company has granted exclusive commercialization rights for Praluent® in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd. as of November 2023, which may streamline marketing and distribution efforts in the region [2].